Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Essiac Eight Herb Complex Ingredients & Drug Interactions

by Swanson

Softgel Capsule Category: Botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Essiac Eight Herb Complex is a dietary supplement by Swanson with 8 active ingredients. Its ingredients are commonly taken for menopause symptoms (hot flashes), high cholesterol, bone health/osteoporosis.Based on those ingredients, 2,193 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Slippery Elm, Kelp, Red Clover. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Essiac Eight Herb Complex by Swanson

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 8 active ingredients.
  • “Essiac Proprietary Herbal Complex” is a proprietary blend — the label gives one combined amount (398 mg) without saying how much of each component you get.

Essiac Eight Herb Complex contains 8 active herbal ingredients: red clover, turkey rhubarb, slippery elm, blessed thistle, burdock root, sheep sorrel, watercress, and kelp. These are blended together in a softgel capsule with inactive ingredients—rice bran oil, gelatin, glycerin, beeswax, deionized water, sunflower lecithin, maltodextrin, caramel color, and natural vanilla flavor—that serve as the capsule base and carriers.

Does it work?

Couldn't assess
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not assessable

We hold no graded evidence for this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: comprehensive immune system defense.
  • Our graded evidence for these ingredients doesn't cover that particular purpose.

The evidence we hold on file does not establish effectiveness for any of the conditions these herbs are traditionally used for. Red clover, turkey rhubarb, slippery elm, blessed thistle, burdock, sheep sorrel, and kelp all carry insufficient reliable evidence ratings for the conditions they're associated with—ranging from menopausal symptoms and bone health to bronchitis, skin conditions, and digestive concerns.

Watercress has no effectiveness ratings in our data. Without established evidence, we can't tell you whether this formula will produce the benefits people often expect from it.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 8 of the 8 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 8 of 8.
  • General safety write-ups exist for 8 of 8.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Red clover is generally well tolerated in the short term but calls for caution because of its estrogen-like activity—avoid it during pregnancy and while breastfeeding. Turkey rhubarb is well tolerated in food amounts but the medicinal root can cause cramping and should not be used long-term; avoid it in pregnancy and while nursing.

Slippery elm is generally well tolerated short-term, though safety data are limited; some sources caution against pregnancy use, and too little information exists for breastfeeding. Blessed thistle is often well tolerated in small amounts but can cause nausea or vomiting at higher doses; it's traditionally thought to affect the uterus, so avoid it in pregnancy, though it's been used to support milk supply—check with your doctor.

Burdock is likely safe as a food and for short-term use but should be avoided in medicinal amounts during pregnancy and breastfeeding. Sheep sorrel is generally safe as a food in normal amounts but has high oxalate content, which can be a concern at larger or concentrated doses; it's possibly safe in pregnancy.

Watercress is generally safe as a food but avoid concentrated supplements; avoid it in pregnancy due to lack of safety data. Kelp's variable, high iodine content can disrupt thyroid function and the plant may concentrate heavy metals—avoid it during pregnancy and while breastfeeding.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 8 of the 8 matched ingredients can interact with medications — Blessed Thistle, Burdock, Rhubarb, Red Clover, Watercress, among others.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; heart-rhythm medications; lithium.
  • For scale: 2,194 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking this product, double-check with your doctor or pharmacist if you're on any blood thinners or antiplatelet drugs (moderate risk from red clover, burdock, sheep sorrel, and kelp), thyroid medications or antithyroid drugs (moderate risk from kelp), estrogen therapy (moderate risk from red clover), methotrexate (moderate risk from red clover), tamoxifen (moderate risk from red clover), lithium (moderate risk from watercress and kelp), diuretics or corticosteroids (moderate risk from turkey rhubarb), or kidney- or liver-protective drugs (moderate risk from turkey rhubarb). Stomach acid reducers—H2-blockers, antacids, and proton pump inhibitors—may have reduced effectiveness (minor risk from blessed thistle).

Any oral medication you take may have slowed absorption (moderate risk from slippery elm). If you're on multiple medications, this product requires a careful review.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with no assessable stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Essiac Eight Herb Complex is a traditional herbal blend, but we have no data showing it's effective for any specific condition. It interacts with a large number of medications across multiple categories—especially blood thinners, thyroid drugs, stomach acid reducers, and drugs your liver processes—and several ingredients are best avoided during pregnancy and breastfeeding.

If you take any prescription medications or are pregnant or nursing, talk it over with your doctor or pharmacist before starting this product.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 8 of 8 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Mar 22, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Essiac Eight Herb Complex, straight from the product label.

Brand Swanson
Barcode (UPC) 087614025483
Net contents 120 Softgel(s)
Market status On market
Date entered into DSLD Mar 22, 2024
DSLD ID 308523
Product type Botanical
Supplement form Softgel Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Women (not pregnant or lactating)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Essiac Eight Herb Complex by Swanson, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Softgel(s)
Maximum serving Sizes:
2 Softgel(s)
Servings per container
120
UPC/BARCODE
087614025483
IngredientAmount% DV
Red Clover0 NP--
Turkey Rhubarb0 NP--
Slippery Elm0 NP--
Essiac Proprietary Herbal Complex398 mg--
Blessed Thistle0 NP--
Burdock root0 NP--
Sheep Sorrel0 NP--
Watercress0 NP--
Kelp0 NP--

Other ingredients: Rice Bran Oil, Gelatin, Glycerin, Beeswax, Water, Deionized, Sunflower Lecithin, Maltodextrin, Caramel color, natural Vanilla flavor

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Provides comprehensive immune system defense Herbal blend based on ancient Ojibwe formula

Immune health

General Statements

Science-Backed Quality Since 1969

Suggested/Recommended/Usage/Directions

Suggested use: As a dietary supplement, for maintenance take one softgel two times per day, morning and evening, and on an empty stomach. For aggressive dosage, take two softgels two times per day.

Brand IP Statement(s)

Essiac Proprietary Eight Herb Formula is used under license from Herbal Balance for Life, Inc.

Precautions

Warning: For adults only. Keep out of reach of children.

Do not take this product if you are pregnant or nursing or if you have or develop diarrhea, abdominal pain, or intestinal obstruction. Consult your healthcare provider before use if you are taking any prescription medications or if you have a medical condition, especially ulcers or kidney stones.

Do not use if seal is broken.

May contain trace amounts of fish and shellfish.

Storage

Store in a cool, dry place. Do not refrigerate.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Formula

Essiac Eight Herb Complex 398 mg per softgel

FDA Statement of Identity

Herbal Supplement

See for yourself

Essiac Eight Herb Complex by Swanson label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Essiac Eight Herb Complex by Swanson

These are the 8 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Softgel(s) Dosage formSoftgel Capsule Servings per container120 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Essiac Proprietary Herbal Complex

398 mg per serving

Other (inactive) ingredients: Rice Bran Oil, Gelatin, Glycerin, Beeswax, Water, Deionized, Sunflower Lecithin, Maltodextrin, Caramel color, Natural Vanilla flavor. These complete the product’s ingredient list but are not active constituents.

Interaction report

Essiac Eight Herb Complex by Swanson Drug Interactions

Want to check YOUR meds against Essiac Eight Herb Complex?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
2,193Drugs
2,135 Moderate 58 Minor

Ingredients driving the most interactions

Slippery Elm 2,022
Kelp 891

Each ingredient & the kinds of drugs it affects

For each ingredient in Essiac Eight Herb Complex with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Slippery Elm1 drug type · 2,022 drugs

Oral Drugs

Theoretically, slippery elm may slow the absorption and reduce serum levels of oral drugs.
Slippery elm inner bark contains mucilage, which may interfere with the absorption of orally administered drugs.

Likelihood Possible Evidence D

Kelp9 drug types · 891 drugs

Amiodarone (Cordarone)

Theoretically, combining Fucus vesiculosus with amiodarone might cause excessively high iodine levels.
Fucus vesiculosus contains high concentrations of iodine. Amiodarone contains 37.3% iodine and can increase iodine levels. Concomitant use might increase the risk of having excessive iodine levels and adversely affecting thyroid function. Monitor thyroid function.

Likelihood Probable Evidence D
Antithyroid Drugs

Due to its iodine content, Fucus vesiculosus might alter the effects of antithyroid drugs.
Fucus vesiculosus contains high concentrations of iodine. Iodine in high doses has been reported to cause both hyperthyroidism and hypothyroidism, depending on the individual's past medical history. Taking Fucus vesiculosus while using antithyroid drugs could alter the effects of the antithyroid drugs.

Likelihood Possible Evidence D
Lithium

Concomitant use of Fucus vesiculosus and lithium has resulted in hyperthyroidism.
There is a case of hyperthyroidism occurring in a patient taking Fucus vesiculosus and lithium. Monitor thyroid hormones closely in patients taking lithium and Fucus vesiculosus concomitantly.

Likelihood Possible Evidence D
Thyroid Hormone

Due to its iodine content, Fucus vesiculosus might alter the effects of thyroid hormone.
Fucus vesiculosus contains high concentrations of iodine. Iodine in high doses has been reported to cause both hyperthyroidism and hypothyroidism, depending on the individual's past medical history. Taking Fucus vesiculosus while using thyroid hormone could alter the effects of thyroid hormone.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, taking Fucus vesiculosus with antiplatelet or anticoagulant drugs might increase the risk of bruising and bleeding.
In vitro evidence suggests that a constituent of Fucus vesiculosus, known as fucoidan, has anticoagulant effects. However, in clinical research, fucoidan does not seem to have significant anticoagulant activity when taken orally, possibly due to poor absorption.

Likelihood Unlikely Evidence D
Cytochrome P450 2C8 (Cyp2C8) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP2C8 substrates might increase the risk for adverse effects.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, inhibits CYP2C8. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP2C9 substrates might increase the risk for adverse effects.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, inhibits CYP2C9. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP2D6 substrates might alter the effects of these substrates.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, both inhibits and induces CYP2D6. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP3A4 substrates might increase the risk for adverse effects.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, inhibits CYP3A4. This interaction has not been reported in humans.

Likelihood Possible Evidence D

Red Clover9 drug types · 867 drugs

Estrogens

Theoretically, concomitant use of large amounts of red clover might interfere with estrogen therapy.
Red clover contains phytoestrogens which might have estrogenic activity in some people. Theoretically, red clover might compete for estrogen receptors and interfere with estrogen-containing drug therapy.

Likelihood Probable Evidence D
Methotrexate (Trexall, Others)

Theoretically, red clover might increase the risk of methotrexate toxicity.
In a case report, a 52-year-old female receiving weekly methotrexate injections for psoriasis developed symptoms of methotrexate toxicity, including severe vomiting and epigastric pain, after three days of taking red clover 430 mg daily. Toxicity resolved after red clover was discontinued. However, no liver function tests or methotrexate levels were reported.

Likelihood Possible Evidence D
Tamoxifen (Nolvadex)

Theoretically, the phytoestrogens in red clover might interfere with tamoxifen.
In vitro and animal research suggests that genistein, a constituent of red clover, might antagonize the antitumor effects of tamoxifen. However, there is some evidence from an animal study that red clover does not reduce the efficacy of tamoxifen. Until more is known, tell patients taking tamoxifen to avoid red clover.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Although some laboratory research suggests that red clover may have anticoagulant and antiplatelet activity, clinical research has not shown this effect.
In vitro research suggests that genistein in red clover has antiplatelet effects, and historically, red clover was thought to have anticoagulant effects due to its coumarin content. However, some experts state that this is unlikely as most natural coumarins have not been shown to have anticoagulant effects, and their content in red clover is low. Additionally, some clinical research in postmenopausal patients found no effect on coagulation or prothrombin time with the use of red clover flowering tops 378 mg daily for 12 months or red clover isoflavone (Rimostil) 50 mg daily for 2 years.

Likelihood Unlikely Evidence B
Caffeine

Theoretically, soy might reduce the clearance of caffeine; however, a small clinical study found no effect.
Red clover contains genistein. Taking genistein 1 gram daily for 14 days seems to inhibit caffeine clearance and metabolism in healthy females. However, this effect does not seem to occur with the lower amounts of genistein found in red clover. A clinical study in healthy postmenopausal individuals shows that taking red clover capsules standardized to contain 60 mg isoflavones twice daily for 14 days does not affect the pharmacokinetics of caffeine.

Likelihood Unlikely Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, red clover might increase levels of drugs metabolized by CYP1A2; however, a small clinical study found no effect.
In vitro evidence shows that red clover inhibits CYP1A2. However, a clinical study in healthy postmenopausal individuals shows that taking red clover capsules standardized to contain 60 mg isoflavones twice daily for 14 days does not affect the pharmacokinetics of caffeine, a CYP1A2 probe substrate.

Likelihood Unlikely Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, red clover might increase the levels and clinical effects of drugs metabolized by CYP2C19.
In vitro evidence suggests that red clover weakly inhibits CYP2C19. This interaction has not been reported in humans.

Likelihood Unlikely Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, red clover might increase levels of drugs metabolized by CYP2C9; however, a small clinical study found no effect.
In vitro evidence suggests that red clover might inhibit CYP2C9. However, a clinical study in healthy postmenopausal individuals shows that taking red clover capsules standardized to contain 60 mg isoflavones twice daily for 14 days does not affect the pharmacokinetics of tolbutamide, a CYP2C9 probe substrate.

Likelihood Unlikely Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, red clover might increase levels of drugs metabolized by CYP3A4; however, a small clinical study found no effect.
In vitro evidence shows that red clover might inhibit CYP3A4 isoenzymes. However, a clinical study in healthy postmenopausal individuals shows that taking red clover capsules standardized to contain 60 mg isoflavones twice daily for 14 days does not affect the pharmacokinetics of alprazolam, a CYP3A4 probe substrate.

Likelihood Unlikely Evidence B

Turkey Rhubarb8 drug types · 658 drugs

Corticosteroids

Theoretically, frequent and high doses of rhubarb might increase the risk of hypokalemia when taken with corticosteroids.
Rhubarb has stimulant laxative effects. Overuse of rhubarb might compound corticosteroid-induced potassium loss.

Likelihood Possible Evidence D
Cyclosporine (Neoral, Sandimmune)

Theoretically, taking rhubarb with cyclosporine might reduce cyclosporine levels.
Animal research shows that co-administration of rhubarb decoction 0.25 or 1 gram/kg with cyclosporine 2.5 mg/kg, decreases cyclosporine maximum plasma concentration and overall exposure levels when compared with taking cyclosporine alone. The authors theorize that rhubarb might reduce cyclosporine bioavailability by inducing of P-glycoprotein and/or cytochrome P450 3A4. However, since rhubarb was administered as a single oral dose and enzyme induction usually occurs after multiple doses, it is possible that cyclosporine absorption was actually reduced via rhubarb's stimulant laxative effects. Also, the composition of the rhubarb decoction was not described.

Likelihood Possible Evidence D
Digoxin (Lanoxin)

Theoretically, overuse of rhubarb might increase the risk of adverse effects when taken with digoxin.
Rhubarb has stimulant laxative effects. Overuse of rhubarb might cause potassium depletion, increasing the risk of digoxin toxicity.

Likelihood Possible Evidence D
Diuretic Drugs

Theoretically, frequent and high doses of rhubarb might increase the risk of hypokalemia.
Rhubarb has stimulant laxative effects. Overuse of rhubarb might cause potassium depletion and compound diuretic-induced potassium loss.

Likelihood Possible Evidence D
Hepatotoxic Drugs

Theoretically, concomitant use of rhubarb with potentially hepatotoxic drugs might increase the risk of developing liver damage.
Some animal research suggests that anthraquinones in rhubarb might have hepatotoxic effects. Also, rhubarb use has been linked to at least 24 cases of liver injury, although details on the dose of rhubarb and duration of use in these cases is unclear.

Likelihood Possible Evidence D
Nephrotoxic Drugs

Theoretically, long-term use of anthraquinones from rhubarb might increase the risk of nephrotoxicity when used with nephrotoxic drugs.
The anthraquinone constituents of rhubarb have been shown to induce nephrotoxicity in animal research. Additionally, in a case report, a 23-year old female presented with kidney failure after taking 6 tablets of a proprietary slimming agent (found to contain the anthraquinones emodin and aloe-emodin from rhubarb) daily for 6 weeks and then adding diclofenac 25 mg 4 times daily for 2 days. The authors postulate that the anthraquinone constituents of rhubarb contributed to the renal dysfunction, and the addition of diclofenac, a nephrotoxic drug, led to renal failure. Until more is known, advise patients to avoid taking rhubarb if they are taking other potentially nephrotoxic drugs.

Likelihood Possible Evidence D
Stimulant Laxatives

Theoretically, rhubarb might increase the risk for fluid and electrolyte loss when taken with other stimulant laxatives.
Rhubarb has stimulant laxative effects. Concomitant use with stimulant laxatives might compound fluid and electrolyte loss.

Likelihood Possible Evidence D
Warfarin (Coumadin)

Theoretically, excessive use of rhubarb might increase the risk of bleeding when taken with warfarin.
Rhubarb has stimulant laxative effects and can cause diarrhea. Diarrhea can increase the effects of warfarin, increase international normalized ratio (INR), and increase the risk of bleeding. Advise patients who take warfarin not to take excessive amounts of rhubarb.

Likelihood Possible Evidence D

Sheep Sorrel3 drug types · 169 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, sorrel might cause additive effects and side effects when used with anticoagulant or antiplatelet drugs.
In vitro, sorrel has been shown to inhibit platelet aggregation. However, this effect has not been reported in humans.

Likelihood Possible Evidence D
Fexofenadine (Allegra)

Sorrel might reduce the effectiveness of fexofenadine by reducing its absorption from the gut.
In vitro research shows that an ethanol extract of sorrel inhibits organic anion-transporting polypeptide 1A2 (OATP1A2), which transports fexofenadine from the intestine into cells. In rats, concomitant administration of sorrel extract with fexofenadine reduces oral absorption of fexofenadine and the area under the plasma concentration-time curve (AUC).

Likelihood Likely Evidence D
Organic Anion-Transporting Polypeptide Substrates (Oatp)

Sorrel might reduce the effectiveness of OATP substrates by reducing their absorption from the gut.
In vitro research shows that sorrel inhibits OATP1A2. Theoretically it may inhibit other OATPs. The OATPs are expressed in the small intestine and liver and transport drugs into cells. Inhibition of OATP may reduce the bioavailability of oral drugs that are substrates of OATP.

Likelihood Possible Evidence D

Burdock root1 drug type · 122 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, taking burdock with anticoagulant or antiplatelet drugs might increase the risk of bleeding.

In vitro research shows that lignans from burdock reduce rabbit platelet aggregation by inhibiting platelet activating factor. This interaction has not been reported in humans.

Likelihood Possible Evidence D

Blessed Thistle3 drug types · 36 drugs

Antacids

Theoretically, blessed thistle might decrease the effectiveness of antacids.
There are reports that blessed thistle increases stomach acid.

Likelihood Possible Evidence D
H2-Blockers

Theoretically, blessed thistle might decrease the effectiveness of H2-blockers.
There are reports that blessed thistle increases stomach acid.

Likelihood Possible Evidence D
Proton Pump Inhibitors (Ppis)

Theoretically, blessed thistle might decrease the effectiveness of PPIs.
There are reports that blessed thistle increases stomach acid.

Likelihood Possible Evidence D

Watercress3 drug types · 6 drugs

Chlorzoxazone (Parafon Forte, Paraflex)

Watercress might reduce the metabolism of chlorzoxazone and increase its effects and side effects. Clinical research in healthy volunteers shows that a single ingestion of watercress 50 grams increases the chlorzoxazone plasma concentration-time curve by about 56% and increases its half-life by about 53%.

Likelihood Probable Evidence B
Lithium

Watercress is thought to have diuretic properties. Theoretically, due to these potential diuretic effects, watercress might reduce excretion and increase levels of lithium.

Likelihood Probable Evidence D
Warfarin (Coumadin)

Watercress contains vitamin K. Consuming large amounts of watercress might antagonize the anticoagulant effects of warfarin.

Likelihood Possible Evidence B
The maker

Brand information

Manufacturer and brand details for Essiac Eight Herb Complex, from the product label.

Swanson

See all Swanson products
Name
Swanson Health Products
City
Fargo
State
ND
ZipCode
58104
Phone Number
1-800-437-4148
Web Address
swanson.com
Pharmacist Counseling Corner

Essiac Eight Herb Complex by Swanson: Common Questions

Does Essiac Eight Herb Complex by Swanson interact with any medications?
Yes. Based on its ingredients, Essiac Eight Herb Complex has a known interaction with 2,193 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Essiac Eight Herb Complex contains 8 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is it safe to take this while I'm pregnant?
No—several ingredients should be avoided. Red clover, turkey rhubarb, watercress, and kelp all carry safety cautions or are listed as possibly unsafe in pregnancy due to uterine effects or excess iodine, and blessed thistle is traditionally thought to affect the uterus. Talk with your doctor before considering it.
Will this help with menopausal symptoms?
We don't have reliable evidence that either red clover or turkey rhubarb—two ingredients in this blend traditionally used for menopause—actually work for that purpose. The evidence is rated insufficient to know if they help.
Can I take this if I'm on warfarin?
Probably not safely. Turkey rhubarb's laxative effects can increase warfarin's blood-thinning action and bleeding risk, watercress contains vitamin K which can work against warfarin, and the data cautions against excessive use. Check with your doctor before taking this product.
What are the most common side effects?
Red clover may cause muscle aches, nausea, and vaginal spotting. Turkey rhubarb can cause cramps, diarrhea, nausea, and vomiting. Blessed thistle at high doses can cause stomach irritation and vomiting. Most of these occur when the herbs are used in larger amounts or long-term.
Does this product contain any fillers?
Yes, it does. The softgel capsule is made with inactive ingredients including gelatin, glycerin, beeswax, rice bran oil, lecithin, maltodextrin, and flavorings, which serve as the capsule shell and carriers for the herbs.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Essiac Eight Herb Complex is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Essiac Eight Herb Complex label
Go deeper

The Full Monographs Behind Essiac Eight Herb Complex’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Red Clover

Interacts with 867 drugs

Red clover is a plant rich in isoflavones (plant compounds with weak estrogen-like activity) that is most often used for menopause symptoms like hot flashes. The evidence is mixed and genera...

Read the full Red Clover monograph →
Herb & supplement monograph

Rhubarb

Interacts with 658 drugs

Rhubarb root has a long history of use as a laxative and in traditional Chinese medicine, and its edible stalks are a common food. Most medicinal claims are backed by limited or low-quality...

Read the full Rhubarb monograph →
Herb & supplement monograph

Slippery Elm

Interacts with 2,022 drugs

Slippery elm is a traditional herbal remedy made from the inner bark of a North American elm tree, used mainly to soothe sore throats and irritated digestive tracts. Its mucilage can coat an...

Read the full Slippery Elm monograph →
Herb & supplement monograph

Blessed Thistle

Interacts with 36 drugs

Blessed thistle is a bitter herb traditionally used to stimulate appetite and ease mild digestive complaints. High-quality human studies are lacking, so its benefits are not well proven. It...

Read the full Blessed Thistle monograph →
Herb & supplement monograph

Burdock

Interacts with 122 drugs

Burdock is a traditional herb most often used for skin problems and as a so-called 'blood purifier,' but high-quality human studies are lacking and most claims are not well proven. It is wid...

Read the full Burdock monograph →
Herb & supplement monograph

Sorrel

Interacts with 169 drugs

Sorrel is a tangy, leafy herb used in cooking and traditional medicine, often for congestion, digestion, and inflammation. Solid human evidence for any health benefit is limited, and its hig...

Read the full Sorrel monograph →
Herb & supplement monograph

Watercress

Interacts with 6 drugs

Watercress is a nutrient-rich leafy green that provides vitamins A, C, and K plus minerals and antioxidant plant compounds. Eaten as a food it is generally safe and healthy for most people,...

Read the full Watercress monograph →
Herb & supplement monograph

Fucus Vesiculosus

Interacts with 891 drugs

Fucus vesiculosus (bladderwrack) is a brown seaweed rich in iodine that has been used traditionally for thyroid concerns, weight, and skin. There is little solid human evidence to support mo...

Read the full Fucus Vesiculosus monograph →
Sources

Sources & How We Checked

Essiac Eight Herb Complex's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 117 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Red Clover 24 references
  1. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17:353-81. PubMed
  2. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  3. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. PubMed
  4. This P, De La Rochefordiere A, Clough K, et al. Phytoestrogens after breast cancer. Endocr Relat Cancer 2001;8:129-34. PubMed
  5. Tice J, Cummings SR, Ettinger B, et al. Few adverse effects of two red clover extracts rich in phytoestrogens: a multicenter, placebo-controlled trial. Alt Ther 2001;7:S33.
  6. Ingram DM, Hickling C, West L, et al. A double-blind randomized controlled trial of isoflavones in the treatment of cyclical mastalgia. The Breast 2002;11:170-4. PubMed
  7. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;1 PubMed
  8. Cheong JL, Bucknall R. Retinal vein thrombosis associated with a herbal phytoestrogen preparation in a susceptible patient. Postgrad Med J 2005;81:266-7.. PubMed
  9. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156-66. PubMed
  10. Hidalgo LA, Chedraui PA, Morocho N, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005;21(5):257-264. PubMed
  11. Campbell MJ, Woodside JV, Honour JW, et al. Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study. Eur J Clin Nutr 2004;58(1):173-179. PubMed
  12. Guerrero JA, Lozano ML, Castillo J, et al. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 2005;3(2):369-376. PubMed
  13. Kondo K, Suzuki Y, Ikeda Y, Umemura K. Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation. Eur J Pharmacol 2002;455(1):53-57. PubMed
  14. Polini N, Rauschemberger MB, Mendiberri J, et al. Effect of genistein and raloxifene on vascular dependent platelet aggregation. Mol Cell Endocrinol 2007;267(1-2):55-62. PubMed
  15. Wuttke W, Jarry H, Seidlova-Wuttke D. Plant-derived alternative treatments for the aging male: facts and myths. Aging Male 2010;13(2):75-81. PubMed
  16. Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric 2012;15(2):115-124. PubMed
  17. Chen, Y., Xiao, C. Q., He, Y. J., Chen, B. L., Wang, G., Zhou, G., Zhang, W., Tan, Z. R., Cao, S., Wang, L. P., and Zhou, H. H. Genistein alters caffeine exposure in healthy female volunteers. Eur.J Clin.Pharmacol. 2011;67(4):347-353. PubMed
  18. Friedman, J. A., Taylor, S. A., McDermott, W., and Alikhani, P. Multifocal and recurrent subarachnoid hemorrhage due to an herbal supplement containing natural coumarins. Neurocrit.Care 2007;7(1):76-80. PubMed
  19. Hooper, L., Madhavan, G., Tice, J. A., Leinster, S. J., and Cassidy, A. Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum.Reprod.Update. 2010;16(6):745-7 PubMed
  20. Orr A and Parker R. Red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate. Menopause Int. 2013;19(3):133-134. PubMed
  21. Clifton-Bligh PB, et al. Red cover isoflavones enriched with formononetin lower serum LDL cholesterol- a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. 2015;69(1):134-142.
  22. Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). 2015. DOI
  23. Ferraris C, Ballestra B, Listorti C, et al. Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen. Breast Cancer Res Treat 2020;180(1):157-65. doi: 10.1007/s1054 PubMed
  24. Chen L, Choi J, Leonard SW, et al. No Clinically Relevant Pharmacokinetic Interactions of a Red Clover Dietary Supplement with Cytochrome P450 Enzymes in Women. J Agric Food Chem. 2020;68(47):13929-13939. PubMed

See these in context on the Red Clover monograph →

Rhubarb 20 references
  1. Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  2. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  3. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  4. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  5. Nusko G, Schneider B, Schneider I, et al. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut 2000;46:651-5. PubMed
  6. Kwan TH, Tong MK, Leung KT, et al. Acute renal failure associated with prolonged intake of slimming pills containing anthraquinones. Hong Kong Med J 2006;12:394-7.
  7. Fairbairn JW. The anthraquinone laxatives. Biological assay and its relation to chemical structure. Pharmacology 1976;14:48-61. PubMed
  8. Siegers, C. P., Hertzberg-Lottin, E., Otte, M., and Schneider, B. Anthranoid laxative abuse--a risk for colorectal cancer? Gut 1993;34(8):1099-1101. PubMed
  9. Fan, J. G. Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease: a multicenter clinical trial. Hepatobiliary.Pancreat.Dis.Int 2004;3(3):375-380.
  10. Yan, M., Zhang, L. Y., Sun, L. X., Jiang, Z. Z., and Xiao, X. H. Nephrotoxicity study of total rhubarb anthraquinones on Sprague Dawley rats using DNA microarrays. J Ethnopharmacol. 4-15-2006; PubMed
  11. Zhang, J. H., Li, L. S., and Zhang, M. Clinical effects of rheum and captopril on preventing progression of chronic renal failure. Chin Med J (Engl.) 1990;103(10):788-793.
  12. Mitsuma, T., Yokozawa, T., Oura, H., and Terasawa, K. [Rhubarb therapy in patients with chronic renal failure (Part 2)]. Nippon Jinzo Gakkai Shi 1987;29(2):195-207.
  13. Wu, C. X. [A preliminary study on the effect of a single Rheum officinale in heavy doses in the treatment of acute icteric hepatitis]. Zhong.Xi.Yi.Jie.He.Za Zhi.(Chinese Journal of Modern Developments in Traditional Medicine) 1984;4(2):88-89.
  14. Jiao, D. H. [Clinical research on the hemostatic effect of rhubarb on peptic ulcer with acute bleeding]. Zhong.Xi.Yi.Jie.He.Za Zhi.(Chinese Journal of Modern Developments in Traditional Medicine) 1984;4(10):597-600, 579.
  15. Jiao, D. H., Ma, Y. H., Chen, S. J., Liu, C. T., Shu, H. N., and Chu, C. M. Resume of 400 cases of acute upper digestive tract bleeding treated by rhubarb alone. Pharmacology 1980;20 Suppl 1:128-130.
  16. Zhang, JH, Yao, XD, Song, Y, and et al. [Long-term treating effects of rhubarb and captopril in delaying the progression of renal failure]. Chinese Kidney Disease Journal 1993;9(4):197-201.
  17. Rehman H, Begum W, Anjum F, Tabasum H, Zahid S. Effect of rhubarb (Rheum emodi) in primary dysmenorrhoea: a single-blind randomized controlled trial. J Complement Integr Med. 2015 Mar;12(1):61-9.
  18. Yu CP, Lin HJ, Lin SP, Shia CS, Chang PH, Hou YC, Hsieh YW. Rhubarb decreased the systemic exposure of cyclosporine, a probe substrate of P-glycoprotein and CYP 3A. Xenobiotica. 2016 Aug;46(8):677-82. PubMed
  19. Byeon JH, Kil JH, Ahn YC, Son CG. Systematic review of published data on herb induced liver injury. J Ethnopharmacol 2019;233:190-6. PubMed
  20. Zhao D, Feng SX, Zhang HJ, et al. Pharmacokinetics, tissue distribution and excretion of five rhubarb anthraquinones in rats after oral administration of effective fraction of anthraquinones from rheum officinale. Xenobiotica. 2021;51(8):916-925. PubMed

See these in context on the Rhubarb monograph →

Slippery Elm 3 references
  1. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  2. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  3. Czarnecki D, Nixon R, Bekhor P, and et al. Delayed prolonged contact urticaria from the elm tree. Contact Dermatitis 1993;28:196-197. PubMed

See these in context on the Slippery Elm monograph →

Blessed Thistle 2 references
  1. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  2. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.

See these in context on the Blessed Thistle monograph →

Burdock 11 references
  1. Iwakami S, Wu JB, Ebizuka Y, Sankawa U. Platelet activating factor (PAF) antagonists contained in medicinal plants: lignans and sesquiterpenes. Chem Pharm Bull (Tokyo) 1992;40:1196-8. PubMed
  2. Sasaki Y, Kimura Y, Tsunoda T, Tagami H. Anaphylaxis due to burdock. Int J Dermatol 2003;42:472-3. PubMed
  3. Rhoads PM, Tong TG, Banner W Jr, Anderson R. Anticholinergic poisonings associated with commercial burdock root tea. J Toxicol Clin Toxicol 1984-85;22:581-4. PubMed
  4. Rodriguez P, Blanco J, Juste S, et al. Allergic contact dermatitis due to burdock (Arctium lappa). Contact Dermatitis 1995;33:134-5.
  5. Kassler, W. J., Blanc, P., and Greenblatt, R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med 1991;151(11):2281-2288. DOI
  6. Chan, Y. S., Cheng, L. N., Wu, J. H., Chan, E., Kwan, Y. W., Lee, S. M., Leung, G. P., Yu, P. H., and Chan, S. W. A review of the pharmacological effects of Arctium lappa (burdock). Inflammopharmacology. 2011;19(5):245-254. PubMed
  7. Breed, F. B. and Kuwabara, T. Burdock ophthalmia. Arch Ophthalmol 1966;75(1):16-20.
  8. Bryson, P. D., Watanabe, A. S., Rumack, B. H., and Murphy, R. C. Burdock root tea poisoning. Case report involving a commercial preparation. JAMA 5-19-1978;239(20):2157. DOI
  9. <p>Fletcher GF<span>, </span>Cantwell JD. Burdock root tea poisoning. JAMA <span>1978 Oct 6;240(15):1586.</span></p> DOI
  10. Latif A, Fichadiya H, Abid F, Capo G. Herbal Teas and Thrombocytopenia: A Curious Case of Yellow Dock and Burdock-Induced Thrombocytopenia. Eur J Case Rep Intern Med 2022;9(3):003247. PubMed
  11. Niazi B, Ahmed K, Ahmed M, Ali S, Song K, Elias S. Drug-Induced Liver Injury from Herbal Liver Detoxification Tea. Case Rep Gastroenterol 2022;16(3):612-617. PubMed

See these in context on the Burdock monograph →

Sorrel 8 references
  1. Neubauer N, Marz RW. Placebo-controlled, randomized, double-blind, clincal trial with Sinupret sugar coated tablets on the basis of a therapy with antibiotics and decongestant nasal drops in acute sinusitis. Phytomedicine 1994;1:177-81.
  2. Marz RW, Ismail C, Popp MA. Action profile and efficacy of a herbal combination preparation for the treatment of sinusitis. Wien Med Wochenschr 1999;149:202-8.
  3. Zick, S. M., Sen, A., Feng, Y., Green, J., Olatunde, S., and Boon, H. Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC). J Altern Complement Med 2006;12(10):971-980. PubMed
  4. Sanz, P. and Reig, R. Clinical and pathological findings in fatal plant oxalosis. A review. Am J Forensic Med Pathol. 1992;13(4):342-345. PubMed
  5. Gniazdowska, B., Doroszewska, G., and Doroszewski, W. [Hypersensitivity to weed pollen allergens in the region of Bygdoszcz]. Pneumonol.Alergol.Pol. 1993;61(7-8):367-372.
  6. Selçuk SN, Gülhan B, Düzova A, Teksam Ö. Acute tubulointerstitial nephritis due to large amount of sorrel (Rumex acetosa) intake. Clin Toxicol (Phila) 2015;53(5):497. PubMed
  7. Ahn JH, Kim J, Rehman NU, Kim HJ, Ahn MJ, Chung HJ. Effect of Rumex Acetosa Extract, a Herbal Drug, on the Absorption of Fexofenadine. Pharmaceutics. 2020;12(6):E547. PubMed
  8. Jeong D, Irfan M, Lee DH, Hong SB, Oh JW, Rhee MH. Rumex acetosa modulates platelet function and inhibits thrombus formation in rats. BMC Complement Med Ther. 2020;20(1):98. PubMed

See these in context on the Sorrel monograph →

Watercress 34 references
  1. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  2. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  3. Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998;64:144-9. PubMed
  4. Bolton-Smith C, Price RJ, Fenton ST, et al. Compilation of a provisional UK database for the phylloquinone (vitamin K1) content of foods. Br J Nutr 2000;83:389-99.
  5. Rondelaud, D., Dreyfuss, G., Bouteille, B., and Darde, M. L. Changes in human fasciolosis in a temperate area: about some observations over a 28-year period in central France. Parasitol.Res 2000;86(9):753-757. PubMed
  6. Sanchez-Sosa, S., Rojas-Ortega, S., Reed-San Roman, G., and Torres-Santana, M. A. [Massive hepatobiliary fascioliasis]. Rev Gastroenterol.Mex. 2000;65(4):179-183.
  7. van Daele, P. L., Madretsma, G. S., and van Agtmael, M. A. [Stomach ache and fever after consumption of watercress in Turkey: fascioliasis]. Ned.Tijdschr.Geneeskd. 9-29-2001;145(39):1896-1899.
  8. Cosme, A., Ojeda, E., Cilla, G., Torrado, J., Alzate, L., Beristain, X., Orive, V., and Arenas, J. [Fasciola hepatica. study of a series of 37 patients]. Gastroenterol.Hepatol. 2001;24(8):375-380.
  9. Martinez-Bebert, K., Rodriguez-Baez, R., Pila-Perez, R., Pila-Pelaez, R., and Tamakloe, K. [Hepatic hematoma caused by fascioliasis]. Gac.Med Mex. 2002;138(3):271-274.
  10. Dreyfuss, G., Vignoles, P., Abrous, M., and Rondelaud, D. Unusual snail species involved in the transmission of Fasciola hepatica in watercress beds in central France. Parasite 2002;9(2):113-120.
  11. Christmann, M., Henrich, R., Mayer, G., and Ell, C. [Infection with fasciola hepatica causing elevated liver-enzyme results and eosinophilia - serologic and endoscopic diagnosis and therapy]. Z.Gastroenterol. 2002;40(9):801-806.
  12. Cosme, A., Ojeda, E., Poch, M., Bujanda, L., Castiella, A., and Fernandez, J. Sonographic findings of hepatic lesions in human fascioliasis. J Clin Ultrasound 2003;31(7):358-363. PubMed
  13. Sapunar, J., Latorre, R., Guerra, M., and Defilippi, C. [Clinical considerations on 2 cases of hepatic fascioliasis. Importance of the imaging examinations]. Bol.Chil.Parasitol. 1992;47(3-4):70-76.
  14. de Gorgolas, M., Torres, R., Verdejo, C., Garay, J., Robledo, A., Ponte, M. C., and Fernandez Guerrero, M. L. [Fasciola hepatica infestation. Biopathology and new diagnostic and therapeutic aspects]. Enferm.Infecc.Microbiol.Clin 1992;10(9):514-519.
  15. Carrada-Bravo, T. [Fascioliasis: diagnosis, epidemiology and treatment]. Rev Gastroenterol.Mex. 2003;68(2):135-142.
  16. Yilmaz, H. and Godekmerdan, A. Human fasciolosis in Van province, Turkey. Acta Trop. 2004;92(2):161-162.
  17. Dobrucali, A., Yigitbasi, R., Erzin, Y., Sunamak, O., Polat, E., and Yakar, H. Fasciola hepatica infestation as a very rare cause of extrahepatic cholestasis. World J Gastroenterol. 10-15-2004;10(20):3076-3077. PubMed
  18. Alvarez-Chacon, R., Garcia-Rosales, J. J., de la Cruz-Otero MC, Wong-Chio, M., Cabrera-Bravo, M., Gomez-Gomez, J. V., and Gamez-Aranda, V. [Fascioliasis in children. A study of 10 cases]. Bol.Med Hosp.Infant Mex. 1992;49(6):365-371.
  19. Mailles, A., Capek, I., Ajana, F., Schepens, C., Ilef, D., and Vaillant, V. Commercial watercress as an emerging source of fascioliasis in Northern France in 2002: results from an outbreak investigation. Epidemiol.Infect. 2006;134(5):942-945.
  20. Cruz, Lopez O., Adan, Pimentel A., Tamariz Cruz, O. J., Munoz, Lopez A., Cruz Lopez, M. C., Cruz Lopez, M. E., and Munoz, Lopez S. [Hepatic fasciolasis diagnosed in state phase]. Rev Gastroenterol Mex. 2006;71(1):59-62.
  21. el Shazly, A. M., Handousa, A. E., Youssef, M. E., Rizk, H., and Hamouda, M. M. Human fascioliasis: a parasitic health problem in Dakahlia Governorate, Egypt. J Egypt.Soc Parasitol. 1991;21(2):553-559.
  22. Cosme, A., Alzate, L., Orive, V., Recasens, M., Torrado, J., Ruiz, I., and Arenas, J. [Laparoscopic findings in liver fascioliasis. Study of 13 cases]. Rev Esp.Enferm.Dig. 1990;78(6):359-362.
  23. Diaz, J., Pina, B., Lastre, M., Rivera, L., and Perez, O. [Epidemic human fascioliasis. Cuba 1983. VI. Clinical study of 40 children in the Hospital Provincial of Sagua la Grande]. G.E.N. 1990;44(4):385-388.
  24. Borie, C., Corona, S., Garin, A., Olea, P., Salcedo, M., Perez, C., and Apt, W. [A family outbreak of acute hepatic fascioliasis]. Rev Med Chil. 1990;118(1):67-72.
  25. Diamond, S. P., Wiener, S. G., and Marks, J. G., Jr. Allergic contact dermatitis to nasturtium. Dermatol.Clin. 1990;8(1):77-80. DOI
  26. Delasalle, P., Beytout, J., Cambon, M., and Bommelaer, G. [Distomatosis: diagnosis and treatment]. Rev Prat. 1-21-1990;40(3):230-236.
  27. Rivera, J. V. and Bermudez, R. H. Radionuclide imaging of the liver in human fascioliasis. Clin Nucl.Med 1984;9(8):450-453. PubMed
  28. Croese, J., Chapman, G., and Gallagher, N. D. Evolution of fascioliasis after eating wild watercress. Aust.N.Z.J.Med. 1982;12(5):525-527. PubMed
  29. Bendezu, P., Frame, A., and Hillyer, G. V. Human fascioliasis in Corozal, Puerto Rico. J Parasitol. 1982;68(2):297-299. DOI
  30. Derrick, E. and Darley, C. Contact dermatitis to nasturtium. Br.J Dermatol 1997;136(2):290-291. PubMed
  31. Narain, K., Biswas, D., Rajguru, S. K., and Mahanta, J. Human distomatosis due to Fasciola hepatica infection in Assam, India. J Commun.Dis 1997;29(2):161-165.
  32. Brinker, F. Herb Contraindications and Drug Interactions. 1998;2nd edition.
  33. Gruenwald, J. PDR for Herbal Medicines. 1998;1st ed.
  34. Clemente M, Miguel MD, Felipe KB, et al. Effect of watercress extract supplementation on lipid profile and oxidative stress markers in overweight people with physical disability: A randomized, double-blind, and placebo-controlled trial. Phytother Res. 202 PubMed

See these in context on the Watercress monograph →

Fucus Vesiculosus 15 references
  1. Goodman GA, Rall TW, Nies AS, Taylor P. The Pharmacological Basis of Therapeutics, 9th ed.
  2. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
  3. Phaneuf D, Cote I, Dumas P, et al. Evaluation of the contamination of marine algae (Seaweed) from the St. Lawrence River and likely to be consumed by humans. Environ Res 1999;80:S175-S182. PubMed
  4. Durig J, Bruhn T, Zurborn KH, et al. Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Thromb Res 1997;85:479-91. PubMed
  5. Conz PA, La Greca G, Benedetti P, et al. Fucus vesiculosus: a nephrotoxic alga? Nephrol Dial Transplant 1998;13:526-7.
  6. Ohye H, Fukata S, Kanoh M, et al. Thyrotoxicosis caused by weight-reducing herbal medicines. Arch Intern Med 2005;165:831-4. PubMed
  7. Okamura K, Inoue K, Omae T. A case of Hashimoto's thyroiditis with thyroid immunological abnormality manifested after habitual ingestion of seaweed. Acta Endocrinol (Copenh) 1978;88:703-12. PubMed
  8. Agarwal SC, Crook JR, Pepper CB. Herbal remedies -- how safe are they? A case report of polymorphic ventricular tachycardia/ventricular fibrillation induced by herbal medication used for obesity. Int J Cardiol 2006;106:260-1. PubMed
  9. Sterling JB, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 2000;43:691-7. PubMed
  10. Catania, M. A., Oteri, A., Caiello, P., Russo, A., Salvo, F., Giustini, E. S., Caputi, A. P., and Polimeni, G. Hemorrhagic cystitis induced by an herbal mixture. South.Med.J. 2010;103(1):90-92. PubMed
  11. Cumashi, A., Ushakova, N. A., Preobrazhenskaya, M. E., D'Incecco, A., Piccoli, A., Totani, L., Tinari, N., Morozevich, G. E., Berman, A. E., Bilan, M. I., Usov, A. I., Ustyuzhanina, N. E., Grachev, A. A., Sanderson, C. J., Kelly, M., Rabinovich, G. A., I
  12. Irhimeh, M. R., Fitton, J. H., and Lowenthal, R. M. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagul.Fibrinolysis 2009;20(7):607-610. PubMed
  13. Arbaizar, B. and Llorca, J. [Fucus vesiculosus induced hyperthyroidism in a patient undergoing concomitant treatment with lithium]. Actas Esp.Psiquiatr. 2011;39(6):401-403.
  14. Church FC, Meade JB, Treanor RE, and et al. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 2-25-1989;264(6):3618-3623. DOI
  15. Mathew L, Burney M, Gaikwad A, et al. Preclinical evaluation of safety of fucoidan extracts from Undaria pinnatifida and Fucus vesiculosus for use in cancer treatment. Integr Cancer Ther 2017;16(4):572-84.

See these in context on the Fucus Vesiculosus monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring